The Pivotal Role of CDKN2A in Esophageal Carcinogenesis: Molecular Mechanisms, Genetic Alterations, and Clinical Implications

Abstract

 Recent attention has been paid to the study of complex interactions of genetic and environmental factors in the pathogenesis of esophageal carcinomas since the development of esophageal carcinoma is complicated by numerous loci. Research on this precise type of neoplasm is still in progress, as it has involved multiple loci. The tumor suppressor gene p16 is one of the major genes, which include absolute genetic alterations, like mutations, deletions, and dysregulation occurring within this region at very early stages of esophageal carcinogenesis. The p16 alterations are morbid homozygous events specific for histotype, this favoring p16 as a candidate marker for diagnosis prognostics even therapeutics. Though extensive studies are necessary with a view to leading to further tests on p16 in large population-based studies, i.e., to develop feasible and valid sample collection approaches. The esophageal carcinogenesis is multifactorial, driven first and foremost by lifestyle risk factors including tobacco smoking, alcohol abuse, and chronic inflammation, but also significant genetic factors. At present, the best-known genetic factor in the development of esophageal carcinoma is the mutation of the p53 gene. But other genes, like p16, are even more critical for defining the onset and progression of esophageal squamous cell carcinoma. This review attempts to shed light on the function of CDKN2A, which is tied to p16, and its important role in ruling out an esophageal cancer diagnosis, development, and management.